http://www.jcps.ac.cn

Journal of Chinese Pharmaceutical Sciences ›› 2019, Vol. 28 ›› Issue (7): 476-483.DOI: 10.5246/jcps.2019.07.046

• Original articles • Previous Articles     Next Articles

Interferon-liposomes prepared to make macroglia maintain M1 phenotype

Yitian Du1,2, Lu Zhang1,2, Yin Zhan1,2, Xinyu Chai1,2, Kaisen Li1,2, Xianrong Qi1,2*   

  1. 1. Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
    2. Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China
  • Received:2019-05-06 Revised:2019-05-27 Online:2019-07-31 Published:2019-06-13
  • Contact: Tel.: +86+010-82801584, E-mail: qixr@bjmu.edu.cn
  • Supported by:

    National Nature Science Foundation of China (Grant No. 81673365 and 81473156).

Abstract:

Macroglia is a crucial macrophage only existing in the central nervous system. During the development of glioma, it can be activated as M2 anti-inflammatory type to promote glioma growth. Interferon-γ (IFN-γ) is an important immunomodulator inglioma microenvironment, which can also activate macroglia as M1 pro-inflammatory type to enhance anti-tumor immune responseand lead to inhibition of glioma growth. Therefore, we utilized IFN-γ to make macroglia maintain M1 phenotype, so that prospectively achieving anti-tumor immunity for glioma therapy. We prepared interferon-γ-liposomes (IFN-Lp) to protect IFN-γ from elimination. IFN-Lp was proved to have strong capability to be phagocytosed and accumulate in macroglia (BV2 cells) to achieve long-term effect. In addition, IFN-Lp could allow BV2 cells to maintain M1 phenotype, showing no impact on its cell viability. These findings will offer new opportunities to achieve enhanced immunotherapy of glioma.

Key words: Interferon-γ, Liposomes, Microglia, Drug delivery

CLC Number: 

Supporting: